Use of Casirivimab and Imdevimab for the Treatment of COVID-19

Ryan Liu; Rohan Mangal; Thor S Stead; Andrew R Barbera; Latha Ganti

doi:10.7759/cureus.27766

Use of Casirivimab and Imdevimab for the Treatment of COVID-19

Cureus. 2022 Aug 8;14(8):e27766. doi: 10.7759/cureus.27766. eCollection 2022 Aug.

Authors

Ryan Liu¹, Rohan Mangal², Thor S Stead³, Andrew R Barbera⁴, Latha Ganti^{5

6

7}

Affiliations

¹ Biology, Cedar Park High School, Cedar Park, USA.
² Medicine, University of Miami Miller School of Medicine, Miami, USA.
³ Medicine, Warren Alpert Medical School of Brown University, Providence, USA.
⁴ Emergency Medicine, Lakeland Regional Health, Lakeland, USA.
⁵ Emergency Medicine, HCA Florida Ocala Hospital, Ocala, USA.
⁶ Emergency Medicine, Envision Physician Services, Plantation, USA.
⁷ Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA.

Abstract

The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2.

Keywords: case report; casirivimab; casirivimab and imdevimab; covid-19; imdevimab; monoclonal antibody treatment for covid-19; regen-cov.

Publication types

Case Reports